Smeglutide inhalation spray and preparation method thereof

By developing the smegglutide inhalation spray, the spray device is used to form fine particles less than 5 μm, the problems of inconvenience in administration and low bioavailability of existing injection and oral tablets are solved, and efficient lung deposition and Absorption improves patient compliance and treatment effect.

CN118976010APending Publication Date: 2024-11-19QILU PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411050527.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-12-05
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing semegglutide injection and oral tablets are inconvenient to dosing, have low bioavailability, poor patient compliance, and drug absorption is affected by diet, making it difficult to achieve efficient lung deposition and absorption.

Method used

Develop a semegglutide inhalation spray, which atomizes the spray device to form fine particles less than 5μm, with a content of 0.01% to 20%. Combined with antibacterial agent, absorption promoter and pH buffering agent, to ensure a high proportion of fine particles. Particles enter the lungs and increase bioavailability.

Benefits of technology

It has achieved the effects of convenient administration, high bioavailability, high lung deposition rate and low irritation, avoiding the absorption of drugs and affecting food, and significantly improving the patient's compliance and treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976010A_ABST
    Figure CN118976010A_ABST
Patent Text Reader

Abstract

The invention provides a semeglutide inhalation spray which is good in patient compliance and high in targeted part bioavailability, and belongs to the technical field of pharmaceutical preparations. The semeglutide inhalation spray comprises an active component semeglutide, a pharmaceutically acceptable bacteriostatic agent and an absorption enhancer, and the content of the active component semeglutide in the inhalation spray is 0.01%-20% according to the weight volume ratio. The semeglutide inhalation spray is simple in prescription, small in toxic and side effects, uniform in spray droplet distribution, high in lung deposition rate, small in irritation, convenient to administrate and suitable for industrial production, and liquid medicine is subjected to atomization administration through an inhalation device. The invention also provides a preparation method of the semeglutide inhalation spray.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application with application number 202211547056.X filed on December 5, 2022. Technical Field

[0002] The invention belongs to the technical field of pharmaceutical preparations and relates to a semaglutide inhalation spray and a preparation method thereof. Background Art

[0003] Inhalation spray refers to a solution, suspension or emulsion that produces an aerosol for inhalation through a predetermined amount or a quantitative nebulizer. When used, the contents are released in the form of mist with the help of pressure from a manual pump, high-pressure gas, ultrasonic vibration or other methods, so that a certain amount of atomized liquid can be inhaled in the form of an aerosol in one breath. Due to its precise dosage, stable dosage, small droplets released, slow running speed and long duration, the inhalable time of the drug and the deposition rate in the lungs are increased, and patient compliance is good.

[0004] Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can bind to and activate the GLP-1 receptor. By mediating the GLP-1 receptor, it stimulates insulin secretion in a glucose-dependent manner and reduces glucagon secretion, thereby achieving the effect of lowering blood sugar. The long-acting mechanism of semaglutide is to connect the lysine at position 26 of the peptide chain to the C18 fatty diacid side chain, which enhances the affinity for albumin, avoids rapid clearance by the kidneys and prevents metabolic degradation, and prolongs the half-life in the body; the 8th position of the peptide chain is modified to α-aminoisobutyric acid to avoid degradation by the DPP-4 enzyme and increase stability; the lysine at position 34 is replaced by arginine to ensure the stability of the C18 side chain at position 26.

[0005] The drug currently on the market in China and abroad is semaglutide injection (trade name: ) and oral semaglutide tablets (trade name ). The specifications of semaglutide injection are 2mg / 1.5mL and 4mg / 3mL. It was first launched in the United States in December 2017, and was approved for marketing in China in April 2021. It is currently available in more than 50 countries and regions including Europe, Canada, and Japan. Semaglutide injection is injected subcutaneously once a week at doses of 0.25mg, 0.5mg, and 1mg, and is used to control blood sugar in type 2 diabetes. Due to the inconvenience of administering the injection and the great psychological barriers faced by patients, the original research company launched oral semaglutide tablets in the United States in September 2019, which are administered once a day. However, due to the low oral bioavailability, the dose was increased to 3mg, 7mg, and 14mg, and the absolute bioavailability was only 0.4% to 1%, and the absorption effect was poor.

[0006] Since the semaglutide injection contains a large amount of propylene glycol isotonic agent (1.4%), there may be certain toxic side effects, and the injection is inconvenient to use and the patient compliance is poor; the oral semaglutide tablets have a complex prescription, low bioavailability, large dosage and cumbersome administration, and drug absorption is seriously affected by diet. There are clear requirements for the time and method of taking the drug. It needs to be taken at least 30 minutes before the first meal every day with no more than 4 ounces of boiled water. Waiting time less than or more than 30 minutes will affect the absorption of the tablets. Therefore, a new dosage form of semaglutide with convenient administration, high bioavailability and good patient compliance is urgently needed in the clinic to replace injection and oral tablets.

[0007] Because the alveoli in the human lungs have a large specific surface area, rich capillary network, thin alveolar epithelial cell layer, and low biological enzyme activity, the inhalation spray can be rapidly absorbed and maintain biological activity after oral inhalation, has no first-pass effect, high bioavailability, is easy to administer and has little irritation. It is expected to replace injection and oral tablets and become the preferred method of administration for semaglutide.

[0008] The viscosity of semaglutide solution increases with the increase of concentration. The particle size distribution of spray droplets of high-concentration solution is large, which makes it difficult to ensure the effective deposition of drug droplets in the lungs. The molecular weight of peptide drugs is large, and there may be certain obstacles to transmembrane absorption. Therefore, the control of semaglutide solution concentration and spray droplet particle size distribution, as well as how to improve the transmembrane bioavailability of the drug are issues that need to be solved to achieve efficient deposition and effective absorption of semaglutide in the lungs. Summary of the invention

[0009] The purpose of the present invention is to provide a new dosage form of semaglutide with good patient compliance and high bioavailability at the targeted site: an inhalation spray.

[0010] The semaglutide inhalation spray of the present invention has a simple prescription and small toxic and side effects; the drug solution is atomized and administered through an inhalation device, the spray droplets are evenly distributed, the lung deposition rate is high, the irritation is small, the administration is convenient, and it is suitable for industrial production.

[0011] A semaglutide inhalation spray of the present invention, wherein the content of semaglutide in the inhalation spray is 0.01% to 20% by weight to volume ratio, wherein the proportion of fine particles less than 5 μm formed by the inhalation spray after atomization by a spray device is not less than 10%;

[0012] Preferably, the proportion of fine particles smaller than 5 μm formed by the inhalation spray after atomization by the spray device is not less than 20%;

[0013] More preferably, the proportion of fine particles smaller than 5 μm formed by the inhalation spray after atomization by the spray device is not less than 30%.

[0014] In the above-mentioned inhalation spray of the present invention, a relatively high proportion of fine particle content ensures the lung deposition and absorption of the drug, and a good therapeutic effect can be achieved after oral inhalation. On the premise of ensuring the therapeutic effect, the drug is convenient to administer, the bioavailability is high, and the patient compliance is good.

[0015] The inhalation spray of the present invention, wherein the mass median aerodynamic diameter (MMAD) of the fine particles formed by the inhalation spray after atomization by the spray device is no more than 10 μm. After inhalation, the spray droplets of smaller particle size can effectively enter the alveoli and be absorbed into the blood to exert a therapeutic effect.

[0016] In some preferred embodiments, the content of semaglutide in the inhalation spray of the present invention is 0.01% to 15% by weight to volume.

[0017] The inhalation spray of the present invention further comprises a pharmaceutically acceptable antibacterial agent, the content of which is 0.01% to 2% by weight volume ratio, wherein the antibacterial agent is selected from: one or more of phenol, benzyl alcohol, benzalkonium chloride, m-phenol, sodium benzoate, chlorobutanol, hydroxypropyl butyl ester, and hydroxypropyl methyl ester; preferably, the antibacterial agent is selected from one or more of phenol, benzyl alcohol, and benzalkonium chloride.

[0018] The inhalation spray of the present invention further comprises a pharmaceutically acceptable antibacterial agent. In some preferred embodiments, the antibacterial agent is selected from phenol or benzyl alcohol, and the weight-to-volume ratio is:

[0019] When the antibacterial agent is phenol, its content in the inhalation spray is 0.45% to 0.65%;

[0020] When the antibacterial agent is benzyl alcohol, its content in the inhalation spray is 0.5% to 1.5%.

[0021] In some embodiments, the inhalation spray of the present invention further comprises an absorption enhancer, the content of which is 0% to 15% by weight to volume ratio. In some preferred embodiments, the content of the absorption enhancer is 0.01% to 10%.

[0022] In some preferred embodiments of the inhalation spray of the present invention, the absorption enhancer is selected from one or more of Tween 20, Tween 80, sodium octanoate, sodium deoxycholate, sodium lauryl sulfate, sucrose laurate, and 8-(2-hydroxybenzamido) sodium octanoate. In some more preferred embodiments, the absorption enhancer is selected from one or more of Tween 80, sodium octanoate, and sucrose laurate.

[0023] The inhalation spray of the present invention further comprises an absorption enhancer. In some other more preferred embodiments, the absorption enhancer is selected from Tween 80, and its content is 0.01% to 0.15% by weight to volume ratio.

[0024] In some embodiments, the inhalation spray of the present invention further comprises a pH buffer selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium citrate, sodium acetate, sodium carbonate, and sodium tartrate; in some preferred embodiments, the pH buffer is selected from one of disodium hydrogen phosphate, sodium dihydrogen phosphate, or a mixture thereof.

[0025] In some preferred embodiments of the inhalation spray of the present invention, the pH value of the inhalation spray is 7.1 to 7.7, and in some more preferred embodiments, the pH value of the inhalation spray is 7.3 to 7.5. Preferably, the pH value of the spray can be adjusted with hydrochloric acid or sodium hydroxide, and other suitable pH adjusting agents such as sulfuric acid, sodium carbonate, sodium bicarbonate, etc. can also be selected.

[0026] The present invention also provides a method for preparing any one of the above-mentioned inhalation sprays, comprising the following steps:

[0027] (1) Take 80% of the prescription volume of water, add the antibacterial agent, absorption promoter, and pH buffer, stir and dissolve, and adjust the pH to 7.1-7.7 with sodium hydroxide and hydrochloric acid;

[0028] (2) adding semaglutide and stirring until completely dissolved;

[0029] (3) Adjust the pH to 7.3-7.5 with sodium hydroxide and hydrochloric acid;

[0030] (4) Add water to make up to the prescribed volume.

[0031] The water in step (4) can be purified water or water for injection. Water for injection is used in large-scale production. The prepared liquid medicine needs to be sterilized and filtered to ensure the sterility of the liquid medicine.

[0032] The advantages of the preparation method are simple process, low cost, and suitability for industrial production. The product obtained by the method has stable quality and is easy to store and transport.

[0033] Compared with the existing injection and oral tablets, the semaglutide inhalation spray of the present invention has the following beneficial effects:

[0034] 1. The present invention provides a new dosage form of semaglutide, namely, an inhalation spray. Compared with the injection of the prior art, the inhalation spray of the present invention is convenient to administer, reduces the pain and psychological pressure of the patient, greatly improves compliance, and is conducive to clinical use; compared with the tablets of the prior art, the prescription is simple, the drug absorption is avoided from being seriously affected by food, the administration is convenient, the bioavailability is high, and the safety is good.

[0035] 2. The pharmaceutical composition of the present invention has a low spray particle size and a high lung deposition rate, especially when Tween 80 and benzyl alcohol are used as excipients, which not only promotes drug absorption and antibacterial properties, but also reduces the spray particle size. The minimum spray particle size is about MMAD5um, which is particularly suitable for inhalation administration. The proportion of fine particles less than 5μm in the spray droplets formed by the drug solution after atomization by the inhalation device is not less than 10%, and in preferred embodiments, it can reach 20%, 30%, or even higher than 40%. The high proportion of fine particle content ensures the lung deposition of the drug.

[0036] 3. In the pharmaceutical composition of the present invention, the use of absorption enhancers Tween 80, sodium caprylate, or sucrose laurate significantly improves the transmembrane absorption efficiency of the drug, so that the bioavailability of the pharmaceutical composition of the present invention when administered by inhalation reaches 37.1% to 52.1%.

[0037] 4. The pharmaceutical composition of the present invention does not contain osmotic pressure regulators such as propylene glycol, thereby avoiding the side effects caused by the use of a large amount of osmotic pressure regulators. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 Bioavailability of inhalation sprays of different formulations (Examples 3-7, 12) administered via the airway of rats relative to subcutaneous injection. DETAILED DESCRIPTION

[0039] The present invention is further described below by multiple groups of specific embodiments. It should be understood that the embodiments of the present invention are only used to illustrate the present invention, rather than to limit the present invention. Technical solutions obtained by simply modifying the present invention or by equivalently replacing the conventional means or active ingredients based on the technical solution of the present invention all belong to the protection scope of the present invention.

[0040] Example 1

[0041] A semaglutide inhalation spray with phenol as an antibacterial agent and a concentration of 2% was prepared. The specific prescription composition is shown in Table 1.

[0042] Table 1

[0043]

[0044] Preparation method:

[0045] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate and phenol, stir to dissolve, and test the pH to 9.1; adjust the pH to 7.5 with dilute hydrochloric acid. Add 1 g of semaglutide, stir to dissolve, adjust the pH to 7.4 with sodium hydroxide, add purified water to 50 mL, test the pH to 7.4, and obtain a 2% semaglutide inhalation spray.

[0046] Example 2

[0047] A 10% semaglutide inhalation spray was prepared with benzalkonium chloride as an antibacterial agent. The specific formulation composition is shown in Table 2.

[0048] Table 2

[0049]

[0050] Preparation method:

[0051] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate and benzalkonium chloride, stir to dissolve, and test the pH to 9.0; adjust the pH to 7.5 with dilute hydrochloric acid. Add 5 g of semaglutide, stir to dissolve, adjust the pH to 7.4 with sodium hydroxide, add purified water to 50 mL, test the pH to 7.5, and obtain a 10% semaglutide inhalation spray.

[0052] Example 3

[0053] A semaglutide inhalation spray with a concentration of 7.5% was prepared using phenol as an antibacterial agent and sodium octanoate as an absorption enhancer. The specific prescription composition is shown in Table 3.

[0054] Table 3

[0055]

[0056] Preparation method:

[0057] Take 40 mL of purified water, add the prescribed amount of disodium hydrogen phosphate anhydrous, phenol, and sodium octanoate, stir to dissolve, detect the pH to be 8.9, and adjust the pH to 7.5 with dilute hydrochloric acid. Add 3.75 g of semaglutide, stir to dissolve, detect the pH to be 7.4, add purified water to make the volume to 50 mL, detect the pH to be 7.3, and obtain a semaglutide inhalation spray with a concentration of 7.5%.

[0058] Example 4

[0059] A semaglutide inhalation spray with a concentration of 7.5% was prepared, with phenol as an antibacterial agent and sucrose laurate as an absorption enhancer. The specific prescription composition is shown in Table 4.

[0060] Table 4

[0061]

[0062] Preparation method:

[0063] Take 40 mL of purified water, add the prescribed amount of disodium hydrogen phosphate anhydrous, phenol, and sucrose laurate, stir to dissolve, and test the pH to be 7.3. Add 3.75 g of semaglutide, stir to dissolve, test the pH to be 7.1, add purified water to make the volume 50 mL, test the pH to be 7.1, and obtain a semaglutide inhalation spray with a concentration of 7.5%.

[0064] Example 5

[0065] A semaglutide inhalation spray with a concentration of 7.5% was prepared using benzyl alcohol as an antibacterial agent and Tween 80 as an absorption enhancer. The specific prescription composition is shown in Table 5.

[0066] Table 5

[0067]

[0068] Preparation method:

[0069] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate, benzyl alcohol, and Tween 80, stir to dissolve, and test the pH to 8.9; adjust the pH to 7.5 with dilute hydrochloric acid. Add 3.75 g of semaglutide, stir to dissolve, adjust the pH to 7.4 with sodium hydroxide, add purified water to 50 mL, test the pH to 7.4, and obtain a semaglutide inhalation spray with a concentration of 7.5%.

[0070] Example 6

[0071] A semaglutide inhalation spray with a concentration of 7.5% was prepared, with benzyl alcohol as an antibacterial agent, Tween 80 and sodium octanoate as absorption enhancers. The specific prescription composition is shown in Table 6.

[0072] Table 6

[0073]

[0074] Preparation method:

[0075] Take 40 mL of purified water, add the prescribed amount of disodium hydrogen phosphate anhydrous, benzyl alcohol, Tween 80, sodium octanoate, stir to dissolve, and detect the pH to be 8.9; adjust the pH to 7.5 with dilute hydrochloric acid. Add 3.75 g of semaglutide, stir to dissolve, add purified water to make up to 50 mL, detect the pH to be 7.4, and obtain a semaglutide inhalation spray with a concentration of 7.5%.

[0076] Example 7

[0077] A semaglutide inhalation spray with a concentration of 7.5% was prepared, with benzyl alcohol as an antibacterial agent, Tween 80 and sucrose laurate as absorption enhancers, and the specific prescription composition is shown in Table 7.

[0078] Table 7

[0079]

[0080] Preparation method:

[0081] Take 40 mL of purified water, add the prescribed amount of disodium hydrogen phosphate anhydrous, benzyl alcohol, Tween 80, and sucrose laurate, stir to dissolve, and test the pH to be 7.2. Add 3.75 g of semaglutide, stir to dissolve, test the pH to be 7.0, add purified water to make the volume 50 mL, test the pH to be 7.1, and obtain a semaglutide inhalation spray with a concentration of 7.5%.

[0082] Example 8

[0083] A 10% semaglutide inhalation spray was prepared with benzyl alcohol as an antibacterial agent and 0.02% Tween 80 as an absorption enhancer. The specific prescription composition is shown in Table 8.

[0084] Table 8

[0085]

[0086] Preparation method:

[0087] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate, benzyl alcohol, and Tween 80, stir and dissolve, and test the pH to be 8.9; adjust the pH to 7.5 with dilute hydrochloric acid. Add 5 g of semaglutide, stir and dissolve, adjust the pH to 7.3 with sodium hydroxide, add purified water to 50 mL, test the pH to be 7.3, and obtain a 10% semaglutide inhalation spray.

[0088] Example 9

[0089] A 10% semaglutide inhalation spray was prepared with benzyl alcohol as an antibacterial agent and 0.1% Tween 80 as an absorption enhancer. The specific prescription composition is shown in Table 9.

[0090] Table 9

[0091]

[0092] Preparation method:

[0093] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate, benzyl alcohol, and Tween 80, stir and dissolve, and detect the pH to be 8.9; adjust the pH to 7.5 with dilute hydrochloric acid. Add 5 g of semaglutide, stir and dissolve, adjust the pH to 7.4 with sodium hydroxide, add purified water to 50 mL, detect the pH to be 7.3, and obtain a 10% semaglutide inhalation spray.

[0094] Example 10

[0095] A 10% semaglutide inhalation spray was prepared with benzyl alcohol as an antibacterial agent and 0.15% Tween 80 as an absorption enhancer. The specific prescription composition is shown in Table 10.

[0096] Table 10

[0097]

[0098] Preparation method:

[0099] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate, benzyl alcohol, and Tween 80, stir and dissolve, and detect the pH to be 9.0; adjust the pH to 7.6 with dilute hydrochloric acid. Add 5 g of semaglutide, stir and dissolve, adjust the pH to 7.6 with sodium hydroxide, add purified water to 50 mL, detect the pH to be 7.7, and obtain a 10% semaglutide inhalation spray.

[0100] Embodiment 11

[0101] A 15% semaglutide inhalation spray was prepared with benzyl alcohol as an antibacterial agent and 0.02% Tween 80 as an absorption enhancer. The specific prescription composition is shown in Table 11.

[0102] Table 11

[0103]

[0104] Preparation method:

[0105] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate, benzyl alcohol, and Tween 80, stir and dissolve, and test the pH to be 8.9; adjust the pH to 7.5 with dilute hydrochloric acid. Add 7.5 g of semaglutide, stir and dissolve, adjust the pH to 7.3 with sodium hydroxide, add purified water to 50 mL, test the pH to be 7.3, and obtain a 15% semaglutide inhalation spray.

[0106] Comparative Example 1

[0107] A semaglutide inhalation spray with a concentration of 20% was prepared. The specific prescription composition is shown in Table 12.

[0108] Table 12

[0109]

[0110] Preparation method:

[0111] 40mL purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate and phenol respectively, stir to dissolve, and detect the pH to be 9.0; adjust the pH to 7.5 with dilute hydrochloric acid. Add 10g of semaglutide, stir to dissolve, adjust the pH to 7.4 with sodium hydroxide, add purified water to 50mL, detect the pH to be 7.4, and obtain a semaglutide inhalation spray with a concentration of 20%.

[0112] Comparative Example 2

[0113] A semaglutide inhalation spray with benzyl alcohol as an antibacterial agent and a concentration of 10% was prepared. The specific prescription composition is shown in Table 13.

[0114] Table 13

[0115]

[0116] Preparation method:

[0117] Take 40 mL of purified water, add the prescribed amount of anhydrous disodium hydrogen phosphate and benzyl alcohol, stir and dissolve, and detect the pH to be 8.9; adjust the pH to 7.5 with dilute hydrochloric acid. Add 5 g of semaglutide, stir and dissolve, adjust the pH to 7.4 with sodium hydroxide, add purified water to 50 mL, detect the pH to be 7.4, and obtain a 10% semaglutide inhalation spray.

[0118] Stability studies

[0119] Accelerated stability test of semaglutide inhalation spray with different formulations:

[0120] The semaglutide inhalation spray prepared in Examples 1 to 10 was placed at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 0 days, 5 days, and 10 days, and samples were taken for analysis. The results are shown in Table 14.

[0121] Table 14

[0122]

[0123] Note: Content (%) is calculated as 1-total impurities (%).

[0124] The results of the accelerated stability test showed that the semaglutide inhalation spray prepared according to the method of Examples 1 to 10 was placed under the conditions of temperature 40°C ± 2°C and relative humidity 75% ± 5% for 5 days and 10 days, and the maximum single impurity was below 0.80%, the total impurity was below 3.38%, and the drug content was above 96.62%. As the observation time increases, the maximum single impurity and total impurity tend to increase. To ensure stability, the product can be stored at 2 to 8°C.

[0125] Aerodynamic particle size distribution test of semaglutide inhalation spray with different formulations

[0126] After the semaglutide inhalation sprays of Examples 1 to 11 and Comparative Examples 1 to 2 were placed at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 0 days, 5 days, and 10 days, respectively, they were assembled with the inhalation device, and the aerodynamic particle size distribution (APSD) of the spray droplets was tested by simulating the human respiratory tract structure with a new generation of cascade impactors (NGI) according to the aerodynamic characteristics determination method of fine particles of inhalation preparations in Part IV of the 2020 Chinese Pharmacopoeia (0951), and the deposition amount of drug particles in the lungs was approximately evaluated. The test data are shown in Table 15 (unit: ug).

[0127] Table 15

[0128]

[0129]

[0130] Using CITDAS analysis software, statistical analysis of NGI detection data at each level is shown in Table 16.

[0131] Table 16

[0132]

[0133]

[0134] The NGI APSD test results show that the fraction of fine particles smaller than 5 μm in the spray droplets of the semaglutide inhalation spray prepared in Examples 1 to 11 is not less than 10%; the mass median aerodynamic diameter (MMAD) is not greater than 10 um, meeting the particle size requirements for inhalation administration.

[0135] The test data of Examples 1, 2, 11 and Comparative Example 1 show that when the concentration of the drug solution increases from 2% to 10%, 15% and 20%, the fraction of fine particles <5μm in the spray droplets decreases sharply, and the lung deposition efficiency is extremely low. The drug solution with a concentration of 20% is no longer suitable for inhalation administration. Therefore, the drug solution concentration controlled below 15% is most suitable for inhalation administration.

[0136] Surprisingly, the spray MMAD of the 7.5% drug solution in Example 5 was 5.09um, which was comparable to the MMAD 4.53um of the 2% drug solution in Example 1, and the fractions of fine particles <5μm were 44.85% and 52.88%, respectively, indicating that the addition of the absorption enhancer Tween 80 and the antibacterial agent benzyl alcohol can effectively reduce the spray particle size of the high-concentration drug solution. In addition, a higher proportion of fine particles can ensure that the drug has a higher lung deposition.

[0137] Comparing Example 2 with Comparative Example 2, the drug concentration of both is 10%, but when benzyl alcohol is used as the antibacterial agent, the MMAD of the spray liquid is 6.38um, which is lower than the MMAD 7.95um of benzalkonium chloride as the antibacterial agent, indicating that the antibacterial agent benzyl alcohol can also reduce the spray particle size. Comparing Examples 8 to 10 with Comparative Example 2, in the liquid with benzyl alcohol as the antibacterial agent, 0.02%, 0.10%, and 0.15% of Tween 80 were added respectively, and the MMAD of the spray liquid was reduced to 5.46um, 4.78um, and 5.16um, respectively, indicating that the combination of benzyl alcohol and Tween 80 can further reduce the spray particle size of semaglutide liquid.

[0138] Pharmacokinetic study of airway administration in rats

[0139] Test methods

[0140] 42 SD rats were weighed one day before administration and randomly divided into 7 groups, each with 6 rats, of which 6 groups were experimental groups, and were respectively given the semaglutide inhalation spray of Examples 3 to 7 and Example 12 (in order to make a more accurate comparison in animal experiments, the main drug concentration of the spray was consistent, and Example 12 was added: Example 12 was different from Example 1 only in the main drug concentration, and other materials, such as excipients, content, and preparation method, were the same as Example 1. The main drug concentration of Example 12 was 7.5%, and the main drug concentration of Example 1 was 2%); Group 1 was the control group, and was given semaglutide injection. Before the experiment, the rats were continuously fed and had free access to water. Each experimental group was administered by inhaling the semaglutide inhalation spray solution through atomization needle after tracheal inhalation: first, the animal was anesthetized by inhaling isoflurane for a short time, the animal was fixed, the animal's mouth was opened, and the oropharynx was pressed with an instrument to expose the trachea, and the pre-filtered solution was sprayed into the trachea through the atomization needle; the control group was administered by subcutaneous injection of semaglutide injection. 0.2 ml of whole blood was collected from the jugular vein of SD rats before administration (0 h), 0.5, 2, 4, 6, 8, 12, 24, 48, and 72 h after administration, and the concentration of semaglutide in rat plasma was quantitatively detected after centrifugation. The specific dosing regimen is shown in Table 17:

[0141] Table 17

[0142]

[0143] Test results

[0144] WinNonLin 8.3 software was used to calculate the pharmacokinetic parameters of the blood drug concentration data of each group according to the non-compartmental model method, and the average value of the data of 6 animals for each parameter was statistically calculated. The results are shown in Table 18:

[0145] Table 18

[0146]

[0147] The results of the pharmacokinetic test showed that compared with Example 12, the relative bioavailability was significantly improved after the addition of the absorption enhancer to the liquid drug prescription, especially the test group of Example 5 reached the highest 52.11%, showing good formulation development potential. Comparison of the various prescriptions showed that Tween 80 and sodium octanoate had the most significant improvement in bioavailability. The peak time of each test group was faster than that of the control group, indicating that inhaled semaglutide was absorbed more rapidly than subcutaneous injection.

Claims

1. A semaglutide inhalation spray, comprising an active ingredient semaglutide, a pharmaceutically acceptable antibacterial agent and an absorption enhancer, wherein the content of the active ingredient semaglutide in the inhalation spray is 0.01% to 20%, preferably 0.01% to 15%, more preferably 7.5% to 15%, and most preferably 7.5% to 10%, by weight to volume ratio.

2. The inhalation spray according to claim 1, wherein the content of the antibacterial agent is 0.01% to 2% by weight to volume ratio, and the antibacterial agent is selected from: one or more of phenol, benzyl alcohol, benzalkonium chloride, m-phenol, sodium benzoate, chlorobutanol, hydroxypropyl butyl ester, and hydroxypropyl methyl ester; preferably, the antibacterial agent is selected from one or more of phenol, benzyl alcohol, and benzalkonium chloride.

3. The inhalation spray according to claim 1, wherein the content of the absorption enhancer is 0% to 15%, preferably 0.01% to 10%, by weight to volume ratio, and the absorption enhancer is selected from: one or more of Tween 20, Tween 80, sodium octanoate, sodium deoxycholate, sodium lauryl sulfate, sucrose laurate, and 8-(2-hydroxybenzamido) sodium octanoate; preferably, the absorption enhancer is selected from one or more of Tween 80, sodium octanoate, and sucrose laurate.

4. The inhalation spray according to claim 1, wherein the antibacterial agent is selected from phenol or benzyl alcohol, measured by weight to volume ratio, When the antibacterial agent is phenol, its content in the inhalation spray is 0.45% to 0.65%; When the antibacterial agent is benzyl alcohol, its content in the inhalation spray is 0.5% to 1.5%.

5. The inhalation spray according to claim 1, wherein the absorption enhancer is selected from Tween 80, and its content is 0.01% to 0.15% by weight to volume ratio.

6. The inhalation spray according to claim 1, further comprising a pH buffer selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium citrate, sodium acetate, sodium carbonate, and sodium tartrate; preferably, the pH buffer is selected from one of disodium hydrogen phosphate, sodium dihydrogen phosphate, or a mixture thereof.

7. The inhalation spray according to claim 1, having a pH value of 6.5 to 8.5, preferably a pH value of 7.1 to 7.7, and more preferably a pH value of 7.3 to 7.

5.

8. The inhalation spray according to claim 1, wherein the proportion of fine particles smaller than 5 μm formed by the inhalation spray after atomization by the spray device is not less than 10%; Preferably, the proportion of fine particles smaller than 5 μm formed by the inhalation spray after atomization by the spray device is not less than 20%; More preferably, the proportion of fine particles smaller than 5 μm formed by the inhalation spray after atomization by the spray device is not less than 30%.

9. The inhalation spray according to claim 1, wherein the mass median aerodynamic diameter (MMAD) of fine particles formed by the inhalation spray after atomization by a spray device is no greater than 10 μm.

10. A method for preparing an inhalation spray according to any one of claims 1 to 9, comprising the following steps: (1) Take 80% of the prescription volume of water, add the antibacterial agent, absorption promoter, and pH buffer, stir and dissolve, and adjust the pH to 7.1-7.7 with sodium hydroxide and hydrochloric acid; (2) adding semaglutide and stirring until completely dissolved; (3) Adjust the pH to 7.3-7.5 with sodium hydroxide and hydrochloric acid; (4) Add water to make up to the prescribed volume.